Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.60 |
| ▸ | F13A1 | P00488 | 11/20 | 0.60 |
| ▸ | TGM1 | P22735 | 8/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | CCNK | O75909 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.47 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998022 | 0.90 | TGM2 (0.61) | TGM2F13A1TGM1GPR119CCNK | |
| SCHEMBL5443778 | 0.89 | TGM2 (0.55) | TGM2F13A1TGM1GPR119TGM3 | |
| SCHEMBL5443775 | 0.89 | TGM2 (0.55) | TGM2F13A1TGM1GPR119TGM3 | |
| SCHEMBL5438605 | 0.88 | TGM2 (0.61) | TGM2F13A1TGM1GPR119CCNK | |
| SCHEMBL5996576 | 0.87 | TGM2 (0.57) | TGM2F13A1TGM1GPR119CCNK | |
| SCHEMBL14490207 | 0.87 | TGM2 (0.64) | TGM2F13A1TGM1GPR119CCNK | |
| SCHEMBL5447139 | 0.84 | TGM2 (0.60) | TGM2F13A1TGM1CCNKCCNA2 | |
| SCHEMBL710366 | 0.82 | TGM2 (0.64) | TGM2F13A1TGM1PKM | |
| SCHEMBL6977155 | 0.79 | TGM2 (0.62) | TGM2F13A1TGM1PKM | |
| SCHEMBL5997830 | 0.79 | TGM2 (0.52) | TGM2F13A1TGM1TGM3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | TGM2 1975/4885F13A1 4382/4885TGM1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.